Articles On Cann Group (ASX:CAN)

ASX200 hits record high driven by US Fed interest rate cut Mining stocks surge as iron ore prices rebound ALS shares drop 10pc, Monadelphous rises on new contracts   The ASX200 hit yet another record high today, boosted by the first inte...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

S&P/ASX 200 rose 1% in June with large caps leading gains with mid, small and emerging companies lagging S&P/ASX 200 financials and consumer staples were the top performers in June with materials the biggest laggard Urea fertiliser...

FDA panel rejects MDMA for PTSD treatment, citing safety and data concerns Advocates argue MDMA’s benefits outweigh risks, call for further research. South Africa legalises personal cannabis use, setting precedent for African nations    G...

Aussie shares down on weaker commodities Iron ore and energy stocks slip, while goldies gain Intel CEO Pat Gelsingers takes swipe at Nvidia’s CEO Jensen Huang   Aussie shares dropped slightly on Tuesday, closing -0.2% lower as the impact...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

As Cann Group (ASX: CAN) looks to finally reap the fruits of its capital-intensive $115 million Mildura production and manufacturing facility, the fast-growing medicinal cannabis company has been pulling out all stops to shore up finances a...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

With a few notable exceptions, ASX cannabis shares widely underperformed again over the last year. That's a far cry from the heady days of 2019 and 2020 when ASX cannabis shares joined their American-listed peers in setting investors' portf...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Albanese govt announces the Future Made in Australia Act Why supporting Australian Made is a win-win game Stockhead reached out to Australian Made CEO, Ben Lazzaro   The ambitiously named Future Made in Australia Act was launched a couple...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Cann Group (ASX: CAN) CEO Peter Koetsier has tendered his resignation just 14 months after assuming leadership of the medicinal cannabis company, which is growing sales at a fast clip but remains burdened by the debts incurred as a result o...

Content Director Patrick Poke of Betashares explores the risks associated with impulsively reacting to investment trends fuelled by media hype, and explain why prudent asset selection, diversification, and maintaining a composed approach ar...

Study shows cannabis can kill melanoma cells Germany has voted to legalise cannabis possession The best performing ASX weed stocks over the past month   It hasn’t been a stellar month for global cannabis stocks, with the index falling by...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Material uncertainties have been raised about two of the largest medicinal cannabis companies listed on the ASX to continue as going concerns, after Cann Group (ASX: CAN) and Althea Group (ASX: AGH) incurred December half losses of $14.3 mi...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month    There are currently at least 3,000 individ...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Jamaican nettletree is said to contain traces of cannabidiol (CBD) Victoria set to launch a medical cannabis driving trial for patients  How ASX weed stocks have performed over the past week and month   Scientists in Brazil said they’ve d...

Cannabis stocks could rise after the removal of US House Speaker Montu says TGA has to allow the term ‘medicinal cannabis’ to be used We look at the best performing ASX weed stocks over the past month   Some experts believe cannabis stock...

Big win for cannabis as SAFER Banking Act set to be passed in the US Australia’s cannabis industry remains robust this year, says TGA We look at how ASX weed stocks have performed over the past weeks   A huge win for cannabis as US SAFER...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Cannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors is the Section 280E of the US IRS tax code We take a look at the best performing weed stocks in last couple of weeks   Having been mauled fo...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Cannabis stocks jumped after marijuana rescheduling recommendation in the US Study in Australia shows cannabis is effective on a range of conditions We take a look at the best performing ASX stocks over the past week   Cannabis stocks ope...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

The US is about to follow Australia’s footsteps and approve psychedelics The FDA is currently awaiting a pivotal survey conducted by MAPS And here’s how the ASX weed stocks have performed over the past week   In July of this year, Austral...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Mastercard says no to weed transactions New York is where weed is happening Jeremy Buckingham pulls a stunt at NSW Parliament   Here’s a quick snapshot of cannabis news making headlines over the past week: Mastercard has told banks to sto...

Medibio jumps after completing Phase 1 clinical trial Cann Group’s latest crop harvest is at a scale twice that of previous harvests 4DMedical wins a $1.1 million from the Fed government   Microcap Medibio (ASX:MEB) jumped 50% this mornin...

Dragonfly Biosciences Limited, a prominent UK-based producer of cannabidiol (CBD) supplements and lotions, is making strides towards its IPO on the ASX next month. Regan Saveall, the CEO of Dragonfly Biosciences, expressed enthusiasm about...

Social media platforms are rushing to update their advertising policies on cannabis Meta was the most recent platform to do so Australia’s TGA is clamping down on CBD advertising in Australia   With regulations on cannabis use moving fast...

Since TGA’s down-scheduling of CBD last year, no products have been sold in Australia But the race to market has been seemingly won by Bod Science following a ‘landmark update’ Stockhead reached out to BOD’s CEO, Jo Patterson   Amidst gro...

Medicinal cannabis company Cann Group (ASX: CAN) will start harvesting again from its Mildura facility in mid-July, with yields set to lift substantially after a financial year when sales more than doubled to reach $13.5 million, bolstered...

Cann Group (ASX:CAN), a prominent player in the Australian medicinal cannabis industry, has announced its unaudited revenue results for the fiscal year 2023, showcasing remarkable growth. The company expects unaudited operating revenue of a...

05 Jul 2023 - Cann Group (ASX:CAN) has announced its unaudited revenue results for the fiscal year 2023, showcasing remarkable growth.

Cann Group’s FY23 sales were 2.1 times that of FY22 Immuron’s FY23 sales increased by 136% from the previous year   Cann Group doubles its sales revenue Cannabis house Cann Group (ASX:CAN) rose 8% this morning after releasing its full yea...

ASX cannabis shares have had a tough year. That’s despite the fact that the cannabis stocks operate in a country where medicinal marijuana is technically legal. That’s enabled them to provide valuable health services to many thousands...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week   As we head into the...

Local markets shook off a post-long-weekend wobble to end the day higher, up 0.23% It’s been another red-hot day for the techies, with that sector up by 3.7%. Health techie AHI went flying 370% this morning, and it’s anyone’s guess as to w...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

The world is experiencing a ‘shroom boom’ Psychedelics are expected to follow in cannabis’ explosive footstep And here’s how the ASX weed stocks have performed, sorted by winners over the past week   For years, people have frowned upon ps...